✦ LIBER ✦

Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen : Long-term follow-up results

✍ Scribed by Luigi Rigacci; Andrea Carpaneto; Renato Alterini; Valentina Carrai; Franco Bernardi; Giampiero Bellesi; Giovanni Longo; Alberto Bosi; Pierluigi Rossi Ferrini

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 99 KB
Volume: 97
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.11032

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

Patients with aggressive non‐Hodgkin lymphoma (NHL) require intensive and extensive therapy, which seems impracticable in elderly patients due to hematologic and extrahematologic toxicity. Consequent dose reduction and therapy attenuation can reduce treatment‐related toxicity but also decreases therapeutic efficacy. Thus, age represents a fundamental prognostic factor that has a profound influence on both therapeutic decisions and patient outcome.

METHODS

Between January, 1990 and June, 1997, 145 patients age > 64 years (median age, 72.3 years) with a diagnosis of aggressive NHL were treated on a chemotherapy regimen that consisted of mitoxantrone, cyclophosphamide, etoposide, and prednisone.

RESULTS

Ninety‐one patients (63%) achieved complete remission, and 48 patients (33%) achieved partial remission, for an overall response rate of 96%. Six patients (4%) were resistant to therapy. The overall survival rate, with a median follow‐up of 66 months, was 44%, and the failure free survival rate was 42%. The disease free survival rate was 63.5%, with a median follow‐up of 60 months. Multivariate survival analysis showed that the achievement of complete remission was the single most important prognostic factor, which was associated significantly with longer survival (P < 0.0001). Toxicity was moderate, with 5 deaths (3%) due to complications related to therapy.

CONCLUSIONS

The current results confirm that a protocol devised specifically for elderly patients may reduce toxicity and allow longer overall survival in this particular subset of patients. Cancer 2003;97:97–104. © 2003 American Cancer Society.

DOI 10.1002/cncr.11032

📜 SIMILAR VOLUMES

Long-term follow-up of patients with int

Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone

✍ Fausto Rossini; Elisabetta Terruzzi; Daniele Perego; Isabella Miccolis; Franca R 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Doxorubicin cardiotoxicity is one of the most serious side effects of the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, regimen, especially among elderly patients. In the CEOP regimen, epirubicin was substituted for doxorubicin to reduce cardiot

Combined chemotherapy with carmustine, d

Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma : A long-term follow-up study

✍ Luigi Rigacci; Valentina Carrai; Luca Nassi; Renato Alterini; Giovanni Longo; Fr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

Cost utility in the United States of rit

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma

✍ John C. Hornberger; Jennie H. Best 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

A randomized trial of hybrid administrat

A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/Cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma : Results of long term follow-up

✍ Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Haruhito Kamei; Kenichi Gemba; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

## BACKGROUND. In an attempt to determine the efficacy of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly alternating chemotherapy, in patients with small cell lung carcinoma (SCLC), the authors conducted a randomized study to

Four versus six courses of a dose-escala

Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation : Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma

✍ Nobert Schmitz; Marita Kloess; Marcel Reiser; Wolfgang E. Berdel; Bernd Metzner; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 252 KB

Long-term follow-up of autologous stem c

Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission : The prognostic value of β2-microglobulin and the tumor score

✍ Issa F. Khouri; Rima M. Saliba; Grace-Julia Okoroji; Sandra A. Acholonu; Richard 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

BACKGROUND. The current study was conducted to analyze the long-term results of autologous stem cell transplantation (ASCT) in patients with diffuse mantle cell lymphoma (MCL) in first disease remission. METHODS. Thirty-three patients were treated. Thirty-one patients had Ann Arbor Stage III or Stag